Description : San Francisco General Hospital is conducting an international clinical trial, partnering with over 100 hospitals and mobile stroke units across North America and other countries, to study intracerebral hemorrhage (ICH), a severe brain injury with no proven treatment. The trial aims to determine if Recombinant Factor VIIa, a medicine used to treat and prevent bleeding, can improve outcomes when given within two hours of symptom onset. Participants will receive either the medicine or a placebo, and some may be enrolled without consent if a family member or representative is not rapidly available. Before starting the study, UCSF researchers will consult with the community and welcome your feedback and questions, as this research may affect you or someone you know.
Pre-presentation Survey:
Please kindly fill out the pre-presentation survey via the following link: shorturl.at/7dOhu